https://www.selleckchem.com/CDK.html
Chronic hepatitis B virus (HBV) infection is a major health problem worldwide. Currently, the first-line treatment for HBV is nucleos(t)ide analogs (NAs) or interferons (IFNs); however, efficient therapeutic approaches that enable cure are lacking. Therefore, novel anti-HBV agents with mechanisms distinct from those of current drugs are needed. Sodium taurocholate cotransporting polypeptide (NTCP) was previously identified as an HBV receptor that is inhibited by several compounds. Farnesoid X receptor (FXR) activation also inhibits NTCP function. In
Like
Comment
Share
